Laurus Bio, a prominent global provider of biomanufacturing-as-a-service (CDMO), has announced the launch of its third precision fermentation manufacturing facility, named R3. The new plant is scheduled to be operational by the third quarter of 2026 and will feature an impressive fermentation capacity of up to 500 kiloliters, along with complete downstream processing capabilities.

This new development builds on the company’s existing infrastructure, which includes a 250 KL state-of-the-art manufacturing facility in Bangalore—India’s hub for biomanufacturing. The R3 facility marks the initial step in Laurus Bio’s larger strategic vision to scale up to a total fermentation capacity of 2 million liters over multiple phases and years.

“Our focus is to be the most trusted, advanced and flexible partner of choice for our customers. Unlike a typical CMO, we have experienced the entire product development lifecycle multiple times. This enables us to add significant value at every step of our customer’s journey, from strain engineering to large scale commercial manufacturing,” said Rajesh Krishnamurthy, CEO of Laurus Bio.

Dr. Satyanarayana Chava, Chairman of the Board at Laurus Bio, emphasized the company’s pioneering efforts and commitment to the field: “Laurus Bio was one of the first companies to build a large-scale fermentation site dedicated for novel proteins and we remain deeply committed to and excited about supporting the syn-bio ecosystem."